Compassionate Use Act of 1996

Target entity: Compassionate Use Act of 1996
Context triple: [California Proposition 215, alsoKnownAs, Compassionate Use Act of 1996]

• A. Orphan Drug Act of 1983
  The Orphan Drug Act of 1983 is a U.S. law that incentivizes the development of treatments for rare diseases by offering benefits such as market exclusivity, tax credits, and research grants to drug manufacturers.
• B. Drug Price Competition and Patent Term Restoration Act of 1984
  The Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, is a U.S. law that streamlined the approval of generic drugs while providing patent term extensions to brand-name drug manufacturers to balance innovation and competition.
• C. Prescription Drug User Fee Act of 1992
  The Prescription Drug User Fee Act of 1992 is a U.S. law that authorizes the FDA to collect fees from pharmaceutical companies to fund and expedite the review of new drug applications.
• D. Rare Diseases Act of 2002
  The Rare Diseases Act of 2002 is a U.S. federal law that expanded national efforts to identify, study, and develop treatments for rare diseases by strengthening research infrastructure and coordination.
• E. National Cancer Act of 1971
  The National Cancer Act of 1971 is a landmark U.S. law that greatly expanded federal funding and coordination for cancer research, prevention, and treatment, helping launch the modern "war on cancer."
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Target entity: Compassionate Use Act of 1996
Target entity description: The Compassionate Use Act of 1996 is a California voter-approved law that legalized medical marijuana use for patients with a physician’s recommendation, making California the first U.S. state to permit medical cannabis.

• A. Orphan Drug Act of 1983
  The Orphan Drug Act of 1983 is a U.S. law that incentivizes the development of treatments for rare diseases by offering benefits such as market exclusivity, tax credits, and research grants to drug manufacturers.
• B. Drug Price Competition and Patent Term Restoration Act of 1984
  The Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, is a U.S. law that streamlined the approval of generic drugs while providing patent term extensions to brand-name drug manufacturers to balance innovation and competition.
• C. Prescription Drug User Fee Act of 1992
  The Prescription Drug User Fee Act of 1992 is a U.S. law that authorizes the FDA to collect fees from pharmaceutical companies to fund and expedite the review of new drug applications.
• D. Rare Diseases Act of 2002
  The Rare Diseases Act of 2002 is a U.S. federal law that expanded national efforts to identify, study, and develop treatments for rare diseases by strengthening research infrastructure and coordination.
• E. National Cancer Act of 1971
  The National Cancer Act of 1971 is a landmark U.S. law that greatly expanded federal funding and coordination for cancer research, prevention, and treatment, helping launch the modern "war on cancer."
• F. None of above. chosen